marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-08-2024
Amicus Therapeutics Balance Sheet 2011-2024 | FOLD
Annual Balance Sheet Amicus Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
149 M | 252 M | 152 M | 233 M | 317 M | 666 M | 425 M | - | 117 M | -9.72 M | -29.2 M | -33.3 M | -24.6 M |
Long Term Debt |
388 M | 392 M | 389 M | 389 M | 150 M | 322 M | 164 M | - | 41.6 M | 10.5 M | 14.2 M | 299 K | - |
Long Term Debt Current |
8.32 M | 8.55 M | 7.41 M | 6.87 M | 7.19 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 245 M | 361 M | 204 M | - | 487 M | 67.6 M | 71.4 M | 31.6 M | 20.9 M |
Total Current Liabilities |
168 M | 139 M | 146 M | 130 M | 129 M | 86.1 M | 70 M | 111 M | 73.6 M | 20.2 M | 10.5 M | 9.24 M | 19.3 M |
Total Liabilities |
618 M | 601 M | 598 M | 600 M | 374 M | 447 M | 274 M | - | 561 M | 87.8 M | 81.8 M | 40.9 M | 40.2 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | 8.5 M |
Retained Earnings |
-2.68 B | -2.53 B | -2.3 B | -2.05 B | -1.77 B | -1.41 B | -1.06 B | - | -580 M | -447 M | -379 M | -319 M | -270 M |
Total Assets |
778 M | 724 M | 905 M | 887 M | 850 M | 790 M | 627 M | - | 908 M | 210 M | 128 M | 110 M | 69.8 M |
Cash and Cash Equivalents |
247 M | 149 M | 245 M | 163 M | 143 M | 79.7 M | 49.1 M | 187 M | 69.5 M | 24.1 M | 43.6 M | 34 M | 25.7 M |
Book Value |
160 M | 123 M | 307 M | 286 M | 476 M | 343 M | 353 M | - | 348 M | 122 M | 45.8 M | 69.2 M | 29.6 M |
Total Shareholders Equity |
160 M | 123 M | 307 M | 286 M | 476 M | 343 M | 353 M | 360 M | 348 M | 122 M | 45.8 M | 69.2 M | 29.6 M |
All numbers in USD currency
Quarterly Balance Sheet Amicus Therapeutics
| 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
389 M | 388 M | 394 M | 393 M | 393 M | 392 M | 391 M | - | 390 M | 389 M | 389 M | 390 M | 390 M | 389 M | 389 M | 389 M | 389 M | 150 M | 150 M | 53.5 M | 53.5 M | - | - | - | - | - | - | - | - | - | 22 M | 21.9 M | 38.5 M | 41.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
617 M | 618 M | 631 M | 619 M | 598 M | 601 M | 627 M | - | 588 M | 598 M | 580 M | 573 M | 559 M | 600 M | 600 M | 600 M | 600 M | 374 M | 374 M | 374 M | 374 M | 447 M | 447 M | 447 M | 447 M | 274 M | 274 M | 274 M | 274 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4 M | - | - | - | 9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.93 M | 8.19 M | 8.5 M | 9.27 M | 8.5 M | 8.5 M |
Retained Earnings |
-2.75 B | -2.68 B | -2.65 B | -2.63 B | -2.59 B | -2.53 B | -2.48 B | - | -2.38 B | -2.3 B | -2.21 B | -2.16 B | -2.11 B | -2.05 B | -2.05 B | -2.05 B | -2.05 B | -1.77 B | -1.77 B | -1.77 B | -1.77 B | -1.41 B | -1.41 B | -1.41 B | -1.41 B | -1.06 B | -1.06 B | -1.06 B | -1.06 B | -780 M | -780 M | -780 M | -780 M | -580 M | -580 M | -580 M | -580 M | -447 M | -447 M | -447 M | -447 M | -379 M | -379 M | -379 M | -379 M | -319 M | -319 M | -319 M | -319 M | -270 M | -270 M | -270 M | -270 M |
Total Assets |
749 M | 778 M | 764 M | 730 M | 701 M | 724 M | 760 M | - | 827 M | 905 M | 957 M | 787 M | 810 M | 887 M | 887 M | 887 M | 887 M | 850 M | 850 M | 850 M | 850 M | 790 M | 790 M | 790 M | 790 M | 627 M | 627 M | 627 M | 627 M | 1.04 B | 1.04 B | 1.04 B | 1.04 B | 908 M | 908 M | 908 M | 908 M | 210 M | 210 M | 210 M | 210 M | 128 M | 128 M | 128 M | 128 M | 110 M | 110 M | 110 M | 110 M | 69.8 M | 69.8 M | 69.8 M | 69.8 M |
Cash and Cash Equivalents |
209 M | 247 M | 263 M | 211 M | 161 M | 149 M | 278 M | 236 M | 233 M | 245 M | 386 M | 177 M | 185 M | 163 M | 163 M | 163 M | 163 M | 143 M | 143 M | 143 M | 143 M | 79.7 M | 79.7 M | 79.7 M | 79.7 M | 49.1 M | 49.1 M | 49.1 M | 49.1 M | 187 M | 187 M | 187 M | 187 M | 69.5 M | 69.5 M | 69.5 M | 69.5 M | 24.1 M | 24.1 M | 24.1 M | 24.1 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 34 M | 34 M | 34 M | 34 M | 25.7 M | 25.7 M | 25.7 M | 25.7 M |
Book Value |
133 M | 160 M | 133 M | 112 M | 103 M | 123 M | 133 M | - | 239 M | 307 M | 377 M | 214 M | 251 M | 286 M | 286 M | 286 M | 286 M | 476 M | 476 M | 476 M | 476 M | 343 M | 343 M | 343 M | 343 M | 353 M | 353 M | 353 M | 353 M | 1.04 B | 1.04 B | 1.04 B | 1.04 B | 908 M | 908 M | 908 M | 908 M | 210 M | 210 M | 210 M | 210 M | 128 M | 128 M | 128 M | 128 M | 110 M | 110 M | 110 M | 110 M | 69.8 M | 69.8 M | 69.8 M | 69.8 M |
Total Shareholders Equity |
133 M | 160 M | 133 M | 112 M | 103 M | 123 M | 133 M | 173 M | 239 M | 307 M | 377 M | 214 M | 251 M | 286 M | 286 M | 286 M | 286 M | 476 M | 476 M | 476 M | 476 M | 343 M | 343 M | 343 M | 343 M | 353 M | 353 M | 353 M | 353 M | 360 M | 360 M | 360 M | 360 M | 348 M | 348 M | 348 M | 348 M | 122 M | 122 M | 122 M | 122 M | 45.8 M | 45.8 M | 45.8 M | 45.8 M | 69.2 M | 69.2 M | 69.2 M | 69.2 M | 29.6 M | 29.6 M | 29.6 M | 29.6 M |
All numbers in USD currency